Bone Morphogenetic Protein 9 Protects against Neonatal Hyperoxia-Induced Impairment of Alveolarization and Pulmonary Inflammation

Aim: Effective treatment of premature infants with bronchopulmonary dysplasia (BPD) is lacking. We hypothesize that bone morphogenetic protein 9 (BMP9), a ligand of the TGF-β family that binds to the activin receptor-like kinase 1 (ALK1)-BMP receptor type 2 (BMPR2) receptor complex, may be a novel therapeutic option for BPD. Therefore, we investigated the cardiopulmonary effects of BMP9 in neonatal Wistar rats with hyperoxia-induced BPD. Methods: Directly after birth Wistar rat pups were exposed to 100% oxygen for 10 days. From day 2 rat pups received BMP9 (2.5 μg/kg, twice a day) or 0.9% NaCl by subcutaneous injection. Beneficial effects of BMP9 on aberrant alveolar development, lung inflammation and fibrosis, and right ventricular hypertrophy (RVH) were investigated by morphometric analysis and cytokine production. In addition, differential mRNA expression of BMP9 and its receptor complex: ALK1, BMPR2, and Endoglin, and of the ALK1 downstream target transmembrane protein 100 (TMEM100) were studied during the development of experimental BPD. Expression of the BMP9 receptor complex and TMEM100 was studied in human endothelial and epithelial cell cultures and the effect of BMP9 on inflammatory cytokine production and TMEM100 expression was studied in endothelial cell cultures. Results: ALK1, ALK2, BMPRII, TMEM100, and Endoglin were differentially expressed in experimental BPD, suggesting a role for BMP9-dependent signaling in the development of (experimental) BPD. TMEM100 was expressed in the wall of blood vessels, showing an elastin-like expression pattern in arterioles. Expression of TMEM100 mRNA and protein was decreased after exposure to hyperoxia. BMP9 treatment of rat pups with hyperoxia-induced experimental BPD reduced alveolar enlargement, lung septal thickness and fibrosis, and prevented inflammation, but did not attenuate vascular remodeling and RVH. The anti-inflammatory effect of BMP9 was confirmed in vitro. Highest expression of ALK1, BMPR2, and TMEM100 was observed in human endothelial cell cultures. Stimulation of human endothelial cell cultures with BMP9 reduced their pro-inflammatory cytokine response and induced TMEM100 expression in pulmonary arterial endothelial cells. Conclusion: BMP9 protects against neonatal hyperoxia-induced BPD by improving aberrant alveolar development, inflammation and fibrosis, demonstrating its therapeutic potential for premature infants with severe BPD.

[1]  N. Morrell,et al.  Bone Morphogenetic Protein 9 Enhances Lipopolysaccharide-Induced Leukocyte Recruitment to the Vascular Endothelium , 2016, The Journal of Immunology.

[2]  E. Cuppen,et al.  Deficiency or inhibition of lysophosphatidic acid receptor 1 protects against hyperoxia‐induced lung injury in neonatal rats , 2016, Acta physiologica.

[3]  Krystle M. Perez,et al.  Sildenafil in Term and Premature Infants: A Systematic Review. , 2015, Clinical therapeutics.

[4]  N. Morrell,et al.  Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension. , 2015, American journal of respiratory and critical care medicine.

[5]  J. Vestbo,et al.  Characterization of spontaneous air space enlargement in mice lacking microfibrillar-associated protein 4. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[6]  S. Gräf,et al.  Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension , 2015, Nature Medicine.

[7]  S. P. Oh,et al.  Essential role for TMEM100 in vascular integrity but limited contributions to the pathogenesis of hereditary haemorrhagic telangiectasia. , 2015, Cardiovascular research.

[8]  B. Thébaud,et al.  Translational Research in Acute Lung Injury and Pulmonary Fibrosis Animal models of bronchopulmonary dysplasia . The term rat models , 2014 .

[9]  G. Cutter,et al.  Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns. , 2014, The Journal of pediatrics.

[10]  V. Bhandari,et al.  Animal models of bronchopulmonary dysplasia. The term mouse models. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[11]  J. West,et al.  BMP Pathway Regulation of and by Macrophages , 2014, PloS one.

[12]  V. Bhandari.  Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia. , 2014, Birth defects research. Part A, Clinical and molecular teratology.

[13]  O. Eickelberg,et al.  Chronic lung disease in the preterm infant. Lessons learned from animal models. , 2013, American journal of respiratory cell and molecular biology.

[14]  R. Morty,et al.  Recent advances in late lung development and the pathogenesis of bronchopulmonary dysplasia. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[15]  D. Bernstein,et al.  FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. , 2013, The Journal of clinical investigation.

[16]  H. Jo,et al.  Anti-Inflammatory and Antiatherogenic Role of BMP Receptor II in Endothelial Cells , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[17]  F. Walther,et al.  Ambrisentan reduces pulmonary arterial hypertension but does not stimulate alveolar and vascular development in neonatal rats with hyperoxic lung injury. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[18]  G. Jenkins,et al.  TGF-β activation and lung fibrosis. , 2012, Proceedings of the American Thoracic Society.

[19]  O. Nakagawa,et al.  Tmem100, an ALK1 receptor signaling-dependent gene essential for arterial endothelium differentiation and vascular morphogenesis , 2012, Proceedings of the National Academy of Sciences.

[20]  P. ten Dijke,et al.  TGFβ Signaling and Cardiovascular Diseases , 2012, International journal of biological sciences.

[21]  F. Walther,et al.  Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[22]  Shaoyi Chen,et al.  Connective tissue growth factor antibody therapy attenuates hyperoxia-induced lung injury in neonatal rats. , 2011, American journal of respiratory cell and molecular biology.

[23]  J. Torday,et al.  Curcumin augments lung maturation, preventing neonatal lung injury by inhibiting TGF-β signaling. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[24]  K. Pietras,et al.  ALK1 as an emerging target for antiangiogenic therapy of cancer. , 2011, Blood.

[25]  E. Bancalari,et al.  CTGF disrupts alveolarization and induces pulmonary hypertension in neonatal mice: implication in the pathogenesis of severe bronchopulmonary dysplasia. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[26]  F. Walther,et al.  Apelin attenuates hyperoxic lung and heart injury in neonatal rats. , 2010, American journal of respiratory and critical care medicine.

[27]  S. P. Oh,et al.  Generation of mice with a conditional and reporter allele for Tmem100 , 2010, Genesis.

[28]  T. Mariani,et al.  PPARγ deficiency results in reduced lung elastic recoil and abnormalities in airspace distribution , 2010, Respiratory research.

[29]  H. Nakanishi,et al.  Transforming growth factor-beta modulates the expression of nitric oxide signaling enzymes in the injured developing lung and in vascular smooth muscle cells. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[30]  R. Steinhorn.  Neonatal pulmonary hypertension , 2010, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[31]  M. Goumans,et al.  Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis , 2010, The Journal of experimental medicine.

[32]  O. Eickelberg,et al.  Transforming growth factor-beta signaling across ages: from distorted lung development to chronic obstructive pulmonary disease. , 2009 .

[33]  F. Walther,et al.  Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury , 2009, Respiratory research.

[34]  R. Trembath,et al.  Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial Cells* , 2009, The Journal of Biological Chemistry.

[35]  N. Morrell,et al.  Altered Bone Morphogenetic Protein and Transforming Growth Factor-β Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease , 2009, Circulation.

[36]  N. French,et al.  Emphysema in young adult survivors of moderate-to-severe bronchopulmonary dysplasia , 2008, European Respiratory Journal.

[37]  Egidio Barbi,et al.  Chronic lung disease after premature birth. , 2008, The New England journal of medicine.

[38]  W. Seeger,et al.  TGF‐β signaling is dynamically regulated during the alveolarization of rodent and human lungs , 2008, Developmental dynamics : an official publication of the American Association of Anatomists.

[39]  Jesse D. Roberts,et al.  TGF-beta-neutralizing antibodies improve pulmonary alveologenesis and vasculogenesis in the injured newborn lung. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[40]  B. Thébaud,et al.  Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. , 2007, American journal of respiratory and critical care medicine.

[41]  M. V. Dinther,et al.  BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis , 2007, Journal of Cell Science.

[42]  L. David,et al.  Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. , 2007, Blood.

[43]  K. Rabe,et al.  Epithelial differentiation is a determinant in the production of eotaxin-2 and -3 by bronchial epithelial cells in response to IL-4 and IL-13. , 2007, Molecular immunology.

[44]  W. Seeger,et al.  Hyperoxia modulates TGF-beta/BMP signaling in a mouse model of bronchopulmonary dysplasia. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[45]  Aiqing He,et al.  The Unfolded Protein Response Is an Important Regulator of Inflammatory Genes in Endothelial Cells , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[46]  S. Abman,et al.  Inhaled NO restores lung structure in eNOS-deficient mice recovering from neonatal hypoxia. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[47]  S. Archer,et al.  Vascular Endothelial Growth Factor Gene Therapy Increases Survival, Promotes Lung Angiogenesis, and Prevents Alveolar Damage in Hyperoxia-Induced Lung Injury: Evidence That Angiogenesis Participates in Alveolarization , 2005, Circulation.

[48]  D. Rifkin,et al.  Growth Factors , Cytokines , Cell Cycle Molecules Lung Alveolar Septation Defects in Ltbp-3-Null Mice , 2010 .

[49]  A. Tanswell,et al.  Opposing effects of 60% oxygen and neutrophil influx on alveologenesis in the neonatal rat. , 2004, American journal of respiratory and critical care medicine.

[50]  J. Szatkowski,et al.  Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery , 2004, Gene Therapy.

[51]  G. Haddad,et al.  Conditional overexpression of bioactive transforming growth factor-beta1 in neonatal mouse lung: a new model for bronchopulmonary dysplasia? , 2004, American journal of respiratory cell and molecular biology.

[52]  F. Walther,et al.  Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. , 2004, Free radical biology & medicine.

[53]  D. Warburton,et al.  Transfer of the active form of transforming growth factor-beta 1 gene to newborn rat lung induces changes consistent with bronchopulmonary dysplasia. , 2003, The American journal of pathology.

[54]  G. Haddad,et al.  Regulation of TGF-beta ligand and receptor expression in neonatal rat lungs exposed to chronic hypoxia. , 2002, Journal of applied physiology.

[55]  C. Heldin,et al.  Activation of bone morphogenetic protein/Smad signaling in bronchial epithelial cells during airway inflammation. , 2002, American journal of respiratory cell and molecular biology.

[56]  C. Heldin,et al.  Activation of the TGF-beta/activin-Smad2 pathway during allergic airway inflammation. , 2001, American journal of respiratory cell and molecular biology.

[57]  K. Rabe,et al.  Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. , 2000, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[58]  D. Warburton,et al.  Bioactive Transforming Growth Factor-Beta in the Lungs of Extremely Low Birthweight Neonates Predicts the Need for Home Oxygen Supplementation , 2000, Neonatology.

[59]  C. Heldin,et al.  The L45 loop in type I receptors for TGF‐β family members is a critical determinant in specifying Smad isoform activation , 1998, FEBS letters.

[60]  K. Lundin,et al.  Cytokine profiles of cultured microvascular endothelial cells from the human intestine , 1998, Gut.

[61]  K. Miyazono,et al.  Cloning and characterization of a human type II receptor for bone morphogenetic proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[62]  A. Tanswell,et al.  α1-Antitrypsin Protects Neonatal Rats from Pulmonary Vascular and Parenchymal Effects of Oxygen Toxicity , 1994, Pediatric Research.

[63]  K. Miyazono,et al.  Characterization of type I receptors for transforming growth factor-beta and activin. , 1994, Science.

[64]  K. Miyazono,et al.  Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta. , 1994, The Journal of biological chemistry.

[65]  M. Dunnill.  Quantitative Methods in the Study of Pulmonary Pathology , 1962, Thorax.